These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 25038877)

  • 1. Leptomeningeal disease and breast cancer: the importance of tumor subtype.
    Abouharb S; Ensor J; Loghin ME; Katz R; Moulder SL; Esteva FJ; Smith B; Valero V; Hortobagyi GN; Melhem-Bertrandt A
    Breast Cancer Res Treat; 2014 Aug; 146(3):477-86. PubMed ID: 25038877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study.
    Huppert LA; Fisch S; Tsopurashvili E; Somepalle SS; Salans M; Vasudevan HN; Jo Chien A; Majure M; Rugo HS; Balassanian R; Boreta L; Melisko ME
    Breast Cancer Res Treat; 2024 Aug; 206(3):625-636. PubMed ID: 38888796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review.
    Wallace G; Kundalia R; Vallebuona E; Cao B; Kim Y; Forsyth P; Soyano A; Smalley I; Pina Y
    Breast Cancer Res; 2024 Mar; 26(1):55. PubMed ID: 38553702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors improving overall survival in breast cancer patients with leptomeningeal disease (LMD): A single institutional retrospective review.
    Wallace G; Kundalia R; Cao B; Kim Y; Smalley I; Forsyth P; Soyano A; Pina Y
    Res Sq; 2023 Jun; ():. PubMed ID: 37333166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population.
    Liu YL; Saraf A; Catanese B; Lee SM; Zhang Y; Connolly EP; Kalinsky K
    Breast Cancer Res Treat; 2018 Jan; 167(1):277-288. PubMed ID: 28948418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival analysis of patients with brain metastases at initial breast cancer diagnosis over the last decade.
    Avila J; Leone J; Vallejo CT; Lin NU; Leone JP
    Breast Cancer Res Treat; 2024 Jun; 205(3):579-587. PubMed ID: 38453783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy for leptomeningeal disease in breast cancer.
    Bartsch R; Jerzak KJ; Larrouquere L; Müller V; Le Rhun E
    Cancer Treat Rev; 2024 Jan; 122():102653. PubMed ID: 38118373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinico-pathologic factors and survival of patients with breast cancer diagnosed with de novo brain metastasis: a national cancer database analysis.
    Hijazi A; Mohanna M; Sabbagh S; Herrán M; Dominguez B; Sarna K; Nahleh Z
    Breast Cancer Res Treat; 2024 Aug; 206(3):527-541. PubMed ID: 38683296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma.
    Horst KC; Hancock SL; Ognibene G; Chen C; Advani RH; Rosenberg SA; Donaldson SS; Hoppe RT
    Ann Oncol; 2014 Apr; 25(4):848-851. PubMed ID: 24608191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of capecitabine for central nervous system metastases from breast cancer.
    Gouveia MC; Hidalgo Filho CM; Moreno RA; Alves HCBR; Ayres AS; Testa L; Bonadio RC
    Ecancermedicalscience; 2023; 17():1638. PubMed ID: 38414937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival and treatment outcomes in patients with leptomeningeal disease from metastatic melanoma.
    Saberian C; Milton DR; Simon J; Amaria RN; Diab A; McQuade J; Patel SP; Tawbi H; Yee C; Wong MK; McCutcheon IE; Davies MA; Ferguson SD; Glitza Oliva IC
    Neurooncol Pract; 2024 Aug; 11(4):452-463. PubMed ID: 39006528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of treatment and outcomes of patients with brain-only metastatic breast cancer.
    Id Said B; Soliman H; Moravan V; Myrehaug S; Tseng CL; Detsky J; Sahgal A; Warner E; Jerzak KJ
    J Neurooncol; 2023 Sep; 164(2):437-445. PubMed ID: 37634217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of risk factors associated with leptomeningeal disease after resection of brain metastases.
    Morshed RA; Saggi S; Cummins DD; Molinaro AM; Young JS; Viner JA; Villanueva-Meyer JE; Goldschmidt E; Boreta L; Braunstein SE; Chang EF; McDermott MW; Berger MS; Theodosopoulos PV; Hervey-Jumper SL; Aghi MK; Daras M
    J Neurosurg; 2023 Aug; 139(2):402-413. PubMed ID: 36640095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries.
    Lamba N; Cagney DN; Catalano PJ; Elhalawani H; Haas-Kogan DA; Wen PY; Wagle N; Lin NU; Aizer AA; Tanguturi S
    Neuro Oncol; 2023 May; 25(5):973-983. PubMed ID: 36367837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival among patients with untreated metastatic breast cancer: "What if I do nothing?".
    Plichta JK; Thomas SM; Wang X; McDuff SGR; Kimmick G; Hwang ES
    Breast Cancer Res Treat; 2024 Jun; 205(2):333-347. PubMed ID: 38438700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of cerebrospinal fluid tumor cell count in leptomeningeal disease from solid tumors.
    Barbour AB; Blouw B; Taylor LP; Graber JJ; McGranahan T; Blau M; Halasz LM; Lo SS; Tseng YD; Venur V; Yang JT
    J Neurooncol; 2024 May; 167(3):509-514. PubMed ID: 38441840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative evaluation of the diagnostic and prognostic performance of CNSide™ versus standard cytology for leptomeningeal disease.
    Appel HR; Rubens M; Roy M; Kotecha R; Hall MD; Mehta MP; Mohler A; Chen Z; Ahluwalia MS; Odia Y
    Neurooncol Adv; 2024; 6(1):vdae071. PubMed ID: 38957163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and Therapeutic Updates in Leptomeningeal Disease.
    Roy-O'Reilly MA; Lanman T; Ruiz A; Rogawski D; Stocksdale B; Nagpal S
    Curr Oncol Rep; 2023 Aug; 25(8):937-950. PubMed ID: 37256537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparisons of clinical characteristics, prognosis, epidemiological factors, and genetic susceptibility between HER2-low and HER2-zero breast cancer among Chinese females.
    Zheng L; Zhang Y; Wang Z; Wang H; Hao C; Li C; Zhao Y; Lyu Z; Song F; Chen K; Huang Y; Song F
    Cancer Med; 2023 Jul; 12(14):14937-14948. PubMed ID: 37387469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-Low Breast Cancer: Molecular Characteristics and Prognosis.
    Agostinetto E; Rediti M; Fimereli D; Debien V; Piccart M; Aftimos P; Sotiriou C; de Azambuja E
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34198891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.